ClinicalTrials.gg
CompletedNCT06023095Updated Jul 17, 2026Results posted

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

A Phase 1 interventional study of LY3502970 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
22nd of 22
24 · median 324
Started
2023
with 5 others
Phase 1
6 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 22nd largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • Safety and Tolerability
  • Chinese
  • LY3502970
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 24 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are native Chinese males or females
  • Have had a stable body weight for the 3 months prior to randomization (less than 5% body weight change) and of ≥ 30.0 kilograms per square meter (kg/m²) or between 27.0 up to 30.0 kg/m² with at least 1 of the following weight-related comorbidities including Hypertension, Dyslipidemia, Cardiovascular disease, Obstructive sleep apnea

Exclusion criteria

Exclusion Criteria:

  • Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus
  • Have used or intend to use any prescription or over-the-counter medications or traditional Chinese treatments within 3 months prior to screening, exception of medications for the treatment of concurrent medical conditions with a stable dose
  • Have known allergies to GLP-1RAs, LY3502970, related compounds, any components of the formulation, or have a history of significant atopy
  • Are overweight or have obesity induced by other endocrinological disorders, diagnosed monogenetic, or syndromic forms of obesity
  • Have or plan to have a surgical, endoscopic or device-based treatment for obesity
  • Have a history or presence of psychiatric disorder, a moderately severe or severe depression status, or a significantly risk for suicide
  • Have a history of acute or chronic pancreatitis
  • Have a known self or family history of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma
  • Have other acute, chronic, or uncontrolled medical conditions, vital organ failure or abnormal laboratory value in the judgment of the investigator would make the participant inappropriate for entry into this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LY3502970 (Cohort 1)

    Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 milligram (mg), 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily (QD) from Day 1 for 16 weeks.

    Drug: LY3502970

  • Experimental
    LY3502970 (Cohort 2)

    Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks.

    Drug: LY3502970

  • Placebo comparator
    Placebo

    Participants received placebo administered orally QD.

    Drug: Placebo

Interventions

  • Administered orally.

  • DrugPlacebo

    Administered orally.

07

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)

    Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.

    Time frame: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)

  2. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)

    Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.

    Time frame: Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)

  3. PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)

    Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.

    Time frame: Cohort 1: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)

  4. PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)

    Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.

    Time frame: Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)

  5. PD: Change From Baseline in Body Mass Index

    PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.

    Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

  6. Pharmacodynamics (PD): Change From Baseline in Body Weight

    PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.

    Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

  7. PD: Change From Baseline in Waist Circumference

    PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.

    Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

  8. PD: Change From Baseline in Fasting Plasma Glucose

    PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline

    Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

08

Results

Posted Jul 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneLY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo
Started10104
Received at least 1 dose of study drug10104
Completed992
Not completed112
Withdrew: Withdrawal by subject002
Withdrew: Protocol deviation100
Withdrew: Adverse event010

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Time frame:
Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)
Reported as:
Count of participants · Participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsLY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo
TEAEs1083
SAEs000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)

Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.

Time frame:
Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)
nanogram per millilitre (ng/mL)LY3502970 (Cohort 1)
Day 5617.6 ± 39
Day 11261.3 ± 43
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)

Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.

Time frame:
Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)
nanogram per millilitre (ng/mL)LY3502970 (Cohort 2)
Day 285.01 ± 44
Day 8435.1 ± 41
Day 140116 ± 42
Day 168159 ± 41
SecondaryPK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)

Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.

Time frame:
Cohort 1: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)
nanogram *hour per milliliter (ng*h/mL)LY3502970 (Cohort 1)
Day 56266 ± 26
Day 1121010 ± 26
SecondaryPK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)

Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.

Time frame:
Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)
nanogram *hour per milliliter (ng*h/mL)LY3502970 (Cohort 2)
Day 2880.4 ± 42
Day 84520 ± 37
Day 1401650 ± 33
Day 1682620 ± 40
SecondaryPD: Change From Baseline in Body Mass Index

PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.

Time frame:
Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
Reported as:
Mean · kilograms per square meter (kg/m²)
PD: Change From Baseline in Body Mass Index
kilograms per square meter (kg/m²)LY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo (Cohort 1)Placebo (Cohort 2)
PD: Change From Baseline in Body Mass Index-2.3046 ± 1.1819-3.5964 ± 1.4441NA ± NANA ± NA
SecondaryPharmacodynamics (PD): Change From Baseline in Body Weight

PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.

Time frame:
Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
Reported as:
Mean · kilograms (kg)
Pharmacodynamics (PD): Change From Baseline in Body Weight
kilograms (kg)LY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo (Cohort 1)Placebo (Cohort 2)
Pharmacodynamics (PD): Change From Baseline in Body Weight-6.156 ± 3.710-10.211 ± 4.011NA ± NANA ± NA
SecondaryPD: Change From Baseline in Waist Circumference

PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.

Time frame:
Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
Reported as:
Mean · centimeters (cm)
PD: Change From Baseline in Waist Circumference
centimeters (cm)LY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo (Cohort 1)Placebo (Cohort 2)
PD: Change From Baseline in Waist Circumference-5.778 ± 2.879-11.667 ± 3.466NA ± NANA ± NA
SecondaryPD: Change From Baseline in Fasting Plasma Glucose

PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline

Time frame:
Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
Reported as:
Mean · millimoles per liter (mmol/L)
PD: Change From Baseline in Fasting Plasma Glucose
millimoles per liter (mmol/L)LY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo (Cohort 1)Placebo (Cohort 2)
PD: Change From Baseline in Fasting Plasma Glucose-0.50 ± 0.45-0.17 ± 0.28NA ± NANA ± NA

Adverse events

Collected over Baseline up to 182 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3502970 (Cohort 1)0/10 (0%)0/10 (0%)10/10 (100%)
LY3502970 (Cohort 2)0/10 (0%)0/10 (0%)10/10 (100%)
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Showing 10 of 66
Most frequent other events
EventLY3502970 (Cohort 1)LY3502970 (Cohort 2)Placebo
NauseaGastrointestinal disorders4/108/100/4
DiarrhoeaGastrointestinal disorders6/107/101/4
Decreased appetiteMetabolism and nutrition disorders7/107/102/4
Upper respiratory tract infectionInfections and infestations4/106/102/4
Abdominal distensionGastrointestinal disorders3/105/100/4
FlatulenceGastrointestinal disorders2/105/100/4
VomitingGastrointestinal disorders4/105/100/4
Protein urine presentInvestigations0/103/102/4
EructationGastrointestinal disorders4/102/100/4
Abdominal painGastrointestinal disorders3/103/100/4

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)LY3502970 (Cohort 1)LY3502970 (Cohort 2)PlaceboTotal
Mean29.8 ± 5.229.8 ± 7.631.5 ± 11.030.1 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)LY3502970 (Cohort 1)LY3502970 (Cohort 2)PlaceboTotal
Female28212
Male82212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3502970 (Cohort 1)LY3502970 (Cohort 2)PlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino1010424
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3502970 (Cohort 1)LY3502970 (Cohort 2)PlaceboTotal
American Indian or Alaska Native0000
Asian1010424
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)LY3502970 (Cohort 1)LY3502970 (Cohort 2)PlaceboTotal
China1010424
09

Study locations

3 sites
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • West China Hospital Sichuan University
    Chengdu, Sichuan 610041, China
  • Shanghai General Hospital
    Shanghai, Songjiang 201620, China
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jul 2024, 10 months.

Results were first posted in Jul 2026, 1 year 11 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 5, 2023
StartActual
Sep 21, 2023
Primary completionActual
Jul 29, 2024
CompletionActual
Jul 29, 2024
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06023095
Responsible party
Sponsor
First posted
Sep 5, 2023
Start date
Sep 21, 2023
Primary completion
Jul 29, 2024
Completion
Jul 29, 2024
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion